Developing Oral LT3 Therapy for Heart Failure - HFrEF
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy
with Liothyronine (LT3) in individuals with heart failure with reduced ejection fraction
(HFrEF) and low triiothyronine (T3) syndrome by conducting a randomized, double-blind,
placebo-controlled cross-over study with a two week washout period between treatments.